Antagonizing HFpEF by Targeting Fibrosis.
作者信息
Bann Glynnis Garry
机构信息
Department of Internal Medicine, Division of Cardiology and the Department of Molecular Biology, the Hamon Center for Regenerative Science and Medicine, and Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Texas Southwestern Medical Center, Dallas, TX.
出版信息
Circulation. 2025 Feb 11;151(6):396-399. doi: 10.1161/CIRCULATIONAHA.124.072973. Epub 2025 Feb 10.
Abstract
摘要
相似文献
1
Antagonizing HFpEF by Targeting Fibrosis.通过靶向纤维化对抗射血分数保留的心力衰竭
Circulation. 2025 Feb 11;151(6):396-399. doi: 10.1161/CIRCULATIONAHA.124.072973. Epub 2025 Feb 10.
2
Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction.心脏重编程和Gata4过表达可减少射血分数保留的心力衰竭中的纤维化并改善舒张功能障碍。
Circulation. 2025 Feb 11;151(6):379-395. doi: 10.1161/CIRCULATIONAHA.123.067504. Epub 2024 Dec 14.
3
CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF.CMR 证实的弥漫性心肌纤维化与 HFpEF 的舒张功能障碍有关。
JACC Cardiovasc Imaging. 2014 Oct;7(10):991-7. doi: 10.1016/j.jcmg.2014.04.022. Epub 2014 Sep 17.
4
Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction.替米沙坦可改善射血分数保留型心力肾衰所致的心肌纤维化和舒张功能障碍。
Exp Biol Med (Maywood). 2021 Dec;246(23):2511-2521. doi: 10.1177/15353702211035058. Epub 2021 Aug 3.
5
Relationship Between Focal and Diffuse Fibrosis Assessed by CMR and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.磁共振评估局灶性和弥漫性纤维化与射血分数保留心力衰竭临床结局的关系。
JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 2):2291-2301. doi: 10.1016/j.jcmg.2018.11.031. Epub 2019 Feb 13.
6
Characterization of a robust mouse model of heart failure with preserved ejection fraction.具有射血分数保留的心衰的稳健小鼠模型的特征描述。
Am J Physiol Heart Circ Physiol. 2023 Aug 1;325(2):H203-H231. doi: 10.1152/ajpheart.00038.2023. Epub 2023 May 19.
7
Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility.小分子靶向 MuRF1 可改善 HFpEF 大鼠模型的心肌舒张功能和骨骼肌收缩力。
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1565-1581. doi: 10.1002/jcsm.12968. Epub 2022 Mar 17.
8
Unraveling Comorbidities Contribution to Cardiac Diastolic Dysfunction and Heart Failure.揭示合并症对心脏舒张功能障碍和心力衰竭的影响
Circ Heart Fail. 2025 Jan;18(1):e011724. doi: 10.1161/CIRCHEARTFAILURE.124.011724. Epub 2024 Nov 29.
9
Simvastatin Attenuates Cardiac Fibrosis under Pathophysiological Conditions of Heart Failure with Preserved Left Ventricular Ejection Fraction by Inhibiting TGF-β Signaling.辛伐他汀通过抑制转化生长因子-β信号通路减轻左心室射血分数保留的心力衰竭病理生理条件下的心脏纤维化。
Pharmacology. 2024;109(1):43-51. doi: 10.1159/000534933. Epub 2023 Nov 28.
10
Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.射血分数保留的心力衰竭中的冠状动脉微血管稀疏和心肌纤维化。
Circulation. 2015 Feb 10;131(6):550-9. doi: 10.1161/CIRCULATIONAHA.114.009625. Epub 2014 Dec 31.
本文引用的文献
1
Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction.心脏重编程和Gata4过表达可减少射血分数保留的心力衰竭中的纤维化并改善舒张功能障碍。
Circulation. 2025 Feb 11;151(6):379-395. doi: 10.1161/CIRCULATIONAHA.123.067504. Epub 2024 Dec 14.
2
Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice.靶向 HDAC6 治疗射血分数保留型心力衰竭的小鼠模型。
Nat Commun. 2024 Feb 26;15(1):1352. doi: 10.1038/s41467-024-45440-7.
3
Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America.心力衰竭流行病学与结局统计：美国心力衰竭学会报告
J Card Fail. 2023 Oct;29(10):1412-1451. doi: 10.1016/j.cardfail.2023.07.006. Epub 2023 Sep 26.
4
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.司美格鲁肽治疗射血分数保留的心力衰竭合并肥胖患者的疗效。
N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25.
5
Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction.直接重编程改善慢性心肌梗死的心脏功能并逆转纤维化。
Circulation. 2023 Jan 17;147(3):223-238. doi: 10.1161/CIRCULATIONAHA.121.058655. Epub 2022 Dec 12.
6
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
7
From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited.从全身炎症到心肌纤维化：再探射血分数保留的心力衰竭。
Circ Res. 2021 May 14;128(10):1451-1467. doi: 10.1161/CIRCRESAHA.121.318159. Epub 2021 May 13.
8
Xbp1s-FoxO1 axis governs lipid accumulation and contractile performance in heart failure with preserved ejection fraction.Xbp1s-FoxO1 轴调控射血分数保留的心力衰竭中的脂质积累和收缩性能。
Nat Commun. 2021 Mar 16;12(1):1684. doi: 10.1038/s41467-021-21931-9.
9
Nitrosative stress drives heart failure with preserved ejection fraction.硝化应激导致射血分数保留型心力衰竭。
Nature. 2019 Apr;568(7752):351-356. doi: 10.1038/s41586-019-1100-z. Epub 2019 Apr 10.
10
Therapeutic approaches for cardiac regeneration and repair.心脏再生和修复的治疗方法。
Nat Rev Cardiol. 2018 Oct;15(10):585-600. doi: 10.1038/s41569-018-0036-6.
Zotero 插件